Response to AASLD editorial/message from the president

Ronald L Koretz; Janus C Jakobsen; Goran Hauser; Dimitrinka Nikolova; Christian Gluud

doi:10.1002/hep.30298

Response to AASLD editorial/message from the president

Ronald L Koretz, Janus C Jakobsen, Goran Hauser, Dimitrinka Nikolova, Christian Gluud

Copenhagen Trial Unit

2 Citations (Scopus)

Abstract

A commentary [1] criticized our systematic review regarding the use of direct-acting agents (DAAs) in chronic hepatitis C [2]. The following represents our major disagreements. Sustained virological response (SVR) is a non-validated surrogate outcome. The principles of evidence-based medicine require that it be validated in randomized clinical trials (RCTs) by showing parallel benefits in clinical outcomes [3]. This article is protected by copyright. All rights reserved.

Original language	English
Journal	Hepatology (Baltimore, Md.)
Volume	69
Issue number	5
Pages (from-to)	2300
ISSN	0270-9139
DOIs	https://doi.org/10.1002/hep.30298
Publication status	Published - 2019

Access to Document

10.1002/hep.30298

Cite this

@article{5e72721dd01045e6a66ca6919e15368f,

title = "Response to AASLD editorial/message from the president",

abstract = "A commentary [1] criticized our systematic review regarding the use of direct-acting agents (DAAs) in chronic hepatitis C [2]. The following represents our major disagreements. Sustained virological response (SVR) is a non-validated surrogate outcome. The principles of evidence-based medicine require that it be validated in randomized clinical trials (RCTs) by showing parallel benefits in clinical outcomes [3]. This article is protected by copyright. All rights reserved.",

author = "Koretz, {Ronald L} and Jakobsen, {Janus C} and Goran Hauser and Dimitrinka Nikolova and Christian Gluud",

year = "2019",

doi = "10.1002/hep.30298",

language = "English",

volume = "69",

pages = "2300",

journal = "Hepatology (Baltimore, Md.)",

issn = "0270-9139",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Response to AASLD editorial/message from the president

AU - Koretz, Ronald L

AU - Jakobsen, Janus C

AU - Hauser, Goran

AU - Nikolova, Dimitrinka

AU - Gluud, Christian

PY - 2019

Y1 - 2019

N2 - A commentary [1] criticized our systematic review regarding the use of direct-acting agents (DAAs) in chronic hepatitis C [2]. The following represents our major disagreements. Sustained virological response (SVR) is a non-validated surrogate outcome. The principles of evidence-based medicine require that it be validated in randomized clinical trials (RCTs) by showing parallel benefits in clinical outcomes [3]. This article is protected by copyright. All rights reserved.

AB - A commentary [1] criticized our systematic review regarding the use of direct-acting agents (DAAs) in chronic hepatitis C [2]. The following represents our major disagreements. Sustained virological response (SVR) is a non-validated surrogate outcome. The principles of evidence-based medicine require that it be validated in randomized clinical trials (RCTs) by showing parallel benefits in clinical outcomes [3]. This article is protected by copyright. All rights reserved.

U2 - 10.1002/hep.30298

DO - 10.1002/hep.30298

M3 - Letter

C2 - 30276829

SN - 0270-9139

VL - 69

SP - 2300

JO - Hepatology (Baltimore, Md.)

JF - Hepatology (Baltimore, Md.)

IS - 5

ER -

Response to AASLD editorial/message from the president

Abstract

Access to Document

Fingerprint

Cite this